The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | ERd in the treatment of newly diagnosed MM
Jesus Berdeja, MD, Director of Myeloma Research, Sarah Cannon Research Institute, Nashville, TN, discusses a phase II study (NCT02843074) to assess the feasibility and tolerance of the combination of elotuzumab, lenalidomide and dexamethasone (ERd) in the induction, consolidation and maintenance treatment of patients with transplant-eligible newly diagnosed multiple myeloma (MM). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
